- freely available
Useful Extend-release Chitosan Tablets with High Antioxidant Activity
AbstractThe antioxidant properties of different low molecular weight (LMW) chitosans (CS1; 22 kDa, CS2; 38 kDa, CS3; 52 kDa, CS4; 81 kDa) were examined for possible use in extended-release tablets. The criteria used were the ability of the chitosans to reduce Cu2+, and hydroxyl and superoxide radicals and N-centered radicals derived from 1,1'-diphenyl-2-picrylhydrazyl, via the use of ESR spectrometry. CS2 showed the highest scavenging activity. CS1 and CS3, however, were much less effective and CS4 was not a viable antioxidant. The results suggest that CS2 could be useful in combating the development of oxidative stress. A series of chitosan tablets were prepared using a spray drying method and evaluated as an extended-release matrix tablet using theophylline (TPH) as a model drug. The release of TPH from the different MW chitosan tablets increased with increasing MW of the chitosan used. CS2, CS3 and CS4 showed a reasonable release activity, but CS1 showed the shortest release activity. Moreover, the CS2-TPH tablet showed the highest scavenging activity of the three chitosan tablets (CS2-CS4) using 2,2’-azinobis (3-ethylbenzothiazoline-6-sulfonic acid) radicals. These results suggest that a CS2-TPH tablet could be potentially useful in an extended-release matrix tablet with a high antioxidant activity.
Share & Cite This Article
Yasufuku, T.; Anraku, M.; Kondo, Y.; Hata, T.; Hirose, J.; Kobayashi, N.; Tomida, H. Useful Extend-release Chitosan Tablets with High Antioxidant Activity. Pharmaceutics 2010, 2, 245-257.View more citation formats
Yasufuku T, Anraku M, Kondo Y, Hata T, Hirose J, Kobayashi N, Tomida H. Useful Extend-release Chitosan Tablets with High Antioxidant Activity. Pharmaceutics. 2010; 2(2):245-257.Chicago/Turabian Style
Yasufuku, Taira; Anraku, Makoto; Kondo, Yuko; Hata, Toshiyuki; Hirose, Junzo; Kobayashi, Nobuyuki; Tomida, Hisao. 2010. "Useful Extend-release Chitosan Tablets with High Antioxidant Activity." Pharmaceutics 2, no. 2: 245-257.